Case Report
Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients
Table 1
GVHD-specific markers prior to initiation of ruxolitinib.
| Test name | Result | Normal range |
| Elafin | >80 ng/mL | 4.9–23.8 ng/mL | ST 1: soluble TNF-receptor 1 | >9.8 ng/mL | <2.5 ng/mL | Reg 3 alpha: regenerating islet-derived 3-alpha | 195.5 ng/mL | <89.0 ng/mL | ST 2: soluble TNF-receptor 2 | >100.0 ng/mL | <30 ng/mL |
|
|